Department of Health and Human Services' logo Department of Health and Human Services

Public Health Service
Food and Drug Administration


San Francisco District
1431 Harbor Bay Parkway
Alameda, CA 84602-7070
Telephone: 510/337-6700

October 18, 2007



Refer to

Dale T. Fowkes
Chief Executive Officer
Health Freedom Nutrition, LLC
255 Bell St., Second Floor
Reno, NV 89503

Dear Mr. Fowkes:

The Food and Drug Administration (FDA) conducted an inspection at your dietary supplement and drug manufacturing facility located at 255 Bell Street, Reno, Nevada on January 30, 2007, February 2 and 6, 2007. This inspection was conducted to determine your firm's compliance with the Federal Food, Drug and Cosmetic Act (the Act) and applicable implementing regulations contained within Title 21 of the Code of Federal Regulations (21 CFR). In addition, the FDA reviewed your web site at (also accessible through on January 31, February 8, May 31, and June 1, 2007. Based on the above referenced inspection and our review of your website, we have concluded that the labeling, marketing and distribution of your products violate the Federal Food, Drug and Cosmetic Act. You can find the Act and implementing regulations through links on FDA's Internet home page at

Under section 201(g)(1)(B) [21 U.S.C. § 321 (g)(1)(8)], articles intended for use in the diagnosis, cure, mitigation, treatment, or prevention of disease are drugs. Moreover, under section 201(g)(1)(C) of the Act [21 U.S.C. § 321(g)(1)(C)], articles other than food that are intended to affect the structure or any function of the body of man are drugs. Based on the claims found in your labeling and on your web site, we have determined that many of your products are promoted for conditions that cause them to be drugs under section 201 (g)(1)(B) and/or 201(g)(1)(C) of the Act. Statements establishing that your products are intended to cure, mitigate, treat, or,prevent disease, or to affect the structure or function of the body, include, but are not limited to, the following:

Huperzine-A (capsules)

Notoginseng Extract (capsules)

Prosera (capsules)

Emblica Extract (capsules)

Cranberry Extract (capsules)

"Cranberry extract has been shown to:

Banaba Leaf Extract (capsules)

Magnolia Extract and Magnolia Max™ (capsules)

Joint Freedom™ (capsule)

Glucosagen On™ (capsule)

• "Reduces pain and inflammation due to arthritis damage."

Devil's Claw Extract (capsule)

TransMis™ (Natural Progesterone Spray)

Linolenic Ester Cream

As noted above, these claims cause your products to be drugs, as defined in section 201(g)(1)(B) and 241(9)(1)(C) of the Act [21 U.S.C. §§ 321 (g)(1)(B) and (C)]. Because these products are not generally recognized as safe and effective when used as labeled, they are new drugs as defined in section 201(p) of the Act [21 U.S.C., § 321 (p)]. Under section 505(a) of the Act [21 U.S.C. § 355(a)], a new drug may not be legally marketed in the United States without an approved New Drug Application (NDA). In addition, your products are misbranded within the meaning of section 502(f)(1) of the Act [21 U.S.C. § 352(f)(1)], in that they lack adequate directions for use.

Further, some of the above products are intended to be used in some manner other than ingestion, such as the TransMist natural Progesterone Spray and the Linolenic Ester Cream. Because they are not ingested, they fail to meet the definition of food or dietary supplement under sections 201 (q and 201 (ff)(2)(A) of the Act [21 U.S.C. § § 321 (f) and 321 (ff)(2)(A)].

TransMist Natural Progesterone Spray is subject to final regulations covering topically applied hormone-containing drug products for over-the-counter (OTC) human use. Under 21 C.F.R. Part 310.530(b), a therapeutic claim for the product, or a claim that the product will affect the structure or function of the body, causes the product to be a new drug.

Based on the labeling claims, the product Linolenic Ester Cream is intended for use as a topical analgesic. The website and label emphasize that the product is "formulated with linolenic esters, a new patented compound which uses the powerful anti-inflammatory effects of omega-3 fatty acids." These ingredients are not being evaluated as topical analgesics under the OTC Drug Review, nor are we aware of any OTC marketing history in the U.S. for these ingredients as topical analgesics. Therefore, this product falls outside of the OTC Review and is a new drug within the meaning of section 201(p) of the Act.

Under sections 301(d) and 505(a) of the Act [21 U.S.C. §§ 331(d) and 355(a)], a new drug may not be introduced or delivered for introduction into interstate commerce unless an FDA-approved application is in effect for it. As noted above, your products are new drugs that do not have approved applications, and their introduction and delivery into interstate commerce violates sections 301(d) and 505(a) of the Act.

In addition, your products are further misbranded within the meaning of section 502(o) of the Act [21 U.S.C. § 352(o)) in that they are drugs manufactured, prepared, propagated, compounded, or processed in an establishment not duly registered under section 510 of the Act [21 U.S.C. 360] and these products have not been listed as required by section 510(j) of the Act [21 U.S.C. 360(j)].

This letter is not intended to be an all-inclusive list of deficiencies of your products and their labeling. It is your responsibility to ensure that labeling and promotional materials for all products distributed by your firm are in compliance with the Act and its implementing regulations. We request that you take prompt action to correct these violations. Failure to promptly correct these violations may, result in enforcement action being initiated by the Food and Drug Administration without further notice. The Act provides for the seizure of illegal products and/or injunction against the manufacturer and/or distributor of illegal products and/or civil money penalties.

Furthermore, this letter is not intended to be an all-inclusive review of the products your firm markets. You are responsible for ensuring that your facility operates in compliance with the Act and its implementing regulations.

Please respond in writing within 15 working days from your receipt of this letter. Your response should outline the specific actions you are taking to correct these violations and to prevent similar violations. You should include in your response documentation such as revised labeling, or other useful information that would assist us in evaluating your corrections. If you cannot complete all corrections before you respond, we expect that you will explain the reason for the delay and state when you will correct any remaining violations.

Your reply should be sent to the attention of Compliance Officer Marshalette O. Edwards at the address on the letterhead.



Barbara Cassens
District Director
San Francisco District

This page was posted on March 27, 2019.

Links to Recommended Companies

  • Compare drug prices and save money at verified online pharmacies.
  • Evaluates the quality of dietary supplement and herbal products.
  • Discount prices, huge inventory, and superb customer service.
  • OnlyMyEmail: Award-winning anti-spam services.
  • 10 Types: Website design, development, and hosting with superb technical support.